Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients

NCT01254279 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01254279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01254279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
December 31, 2014
Enrollment
984 (actual)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic